These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 19514613)

  • 21. [Retreatment options for patients with chronic hepatitis C].
    Hrstić I; Ostojić R; Vucelić B
    Acta Med Croatica; 2009 Dec; 63(5):417-22. PubMed ID: 20198901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and tolerability of pegylated interferon-alpha2a plus ribavirin versus pegylated interferon-alpha2b plus ribavirin in treatment-naive chronic hepatitis C patients.
    Lee S; Kim IH; Kim SH; Kim SW; Lee SO; Lee ST; Kim DG; Lee CS; Choi CS; Cho EY; Kim HC
    Intervirology; 2010; 53(3):146-53. PubMed ID: 20068348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin.
    Martinot-Peignoux M; Stern C; Maylin S; Ripault MP; Boyer N; Leclere L; Castelnau C; Giuily N; El Ray A; Cardoso AC; Moucari R; Asselah T; Marcellin P
    Hepatology; 2010 Apr; 51(4):1122-6. PubMed ID: 20069649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
    Napoli N; Giannelli G; Antonaci A; Antonaci S
    J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection.
    Lagging M; Langeland N; Pedersen C; Färkkilä M; Buhl MR; Mørch K; Dhillon AP; Alsiö A; Hellstrand K; Westin J; Norkrans G;
    Hepatology; 2008 Jun; 47(6):1837-45. PubMed ID: 18454508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4.
    Martín-Carbonero L; Puoti M; García-Samaniego J; De Luca A; Losada E; Quinzan G; Bruno R; Mariño A; González M; Núñez M; Soriano V
    J Viral Hepat; 2008 Oct; 15(10):710-5. PubMed ID: 18637070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads.
    Sezaki H; Suzuki F; Akuta N; Yatsuji H; Hosaka T; Kobayashi M; Suzuki Y; Arase Y; Ikeda K; Miyakawa Y; Kumada H
    Intervirology; 2009; 52(1):43-8. PubMed ID: 19372703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eight-week regimen of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C with hepatitis C virus genotype 2 and a rapid virological response.
    Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kanamori A; Atsumi H; Nakano S; Arakawa T
    Liver Int; 2009 Jan; 29(1):120-5. PubMed ID: 18384519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
    Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
    Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance.
    Khattab M; Emad M; Abdelaleem A; Eslam M; Atef R; Shaker Y; Hamdy L
    Liver Int; 2010 Mar; 30(3):447-54. PubMed ID: 19919569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical trial: extended treatment duration of peginterferon-alpha2b plus ribavirin for 72 and 96 weeks in hepatitis C genotype 1-infected late responders.
    Nagaki M; Shimizu M; Sugihara JI; Tomita E; Sano C; Naiki T; Kimura K; Amano K; Sakai T; Ninomiya M; Kojima T; Katsumura N; Fujimoto M; Moriwaki H
    Aliment Pharmacol Ther; 2009 Aug; 30(4):343-51. PubMed ID: 19485982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can zinc levels predict response to pegylated-interferon and ribavirin therapy in hepatitis C genotype 4 infected Egyptian patients?
    Mohamed AA; Abbassi MM; Hamed WA; EzzEl-Arab MA; Aref AM
    Acta Gastroenterol Belg; 2014 Jun; 77(2):217-23. PubMed ID: 25090819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical trial: a randomized trial of pegylated-interferon-alpha-2a plus ribavirin with or without amantadine in treatment-naïve or relapsing chronic hepatitis C patients.
    Langlet P; D'Heygere F; Henrion J; Adler M; Delwaide J; Van Vlierberghe H; Mulkay JP; Lasser L; Brenard R; Horsmans Y; Michielsen P; Laureys A; Nevens F
    Aliment Pharmacol Ther; 2009 Aug; 30(4):352-63. PubMed ID: 19485978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A triple combination therapy of simeprevir, pegylated-interferon and ribavirin with chronic hepatitis C virus genotype 1 infection].
    Suzuki S; Izumi N
    Nihon Rinsho; 2015 Feb; 73(2):266-72. PubMed ID: 25764681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy of combined antiviral therapy with pegylated interferon alpha-2a and ribavirin for chronic hepatitis C infection in intravenous drug users].
    Ruzić M; Milotka F; Klasnja B; Pobor M; Svarc D; Jovelic A; Fabri I
    Srp Arh Celok Lek; 2010; 138(1-2):43-9. PubMed ID: 20425908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infection.
    Alsiö A; Jannesson A; Langeland N; Pedersen C; Färkkilä M; Buhl MR; Mørch K; Westin J; Hellstrand K; Norkrans G; Lagging M;
    Eur J Clin Microbiol Infect Dis; 2012 Jul; 31(7):1631-5. PubMed ID: 22113307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response prediction and treatment tailoring for chronic hepatitis C virus genotype 1 infection.
    Lindh M; Alestig E; Arnholm B; Eilard A; Hellstrand K; Lagging M; Wahlberg T; Wejstål R; Westin J; Norkrans G
    J Clin Microbiol; 2007 Aug; 45(8):2439-45. PubMed ID: 17581934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Study of nitric oxide in patients with chronic hepatitis C genotype 4: relationship to viremia and response to antiviral therapy.
    Zaki Mel S; Saudy N; El Diasty A
    Immunol Invest; 2010; 39(6):598-610. PubMed ID: 20653427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Results of antiviral treatment of patients with chronic hepatitis C: experience of Poznan centre.
    Bura M; Kowala-Piaskowska A; Adamek A; Bura A; Czajka A; Hryckiewicz K; Bereszyńska I; Mozer-Lisewska I
    Postepy Hig Med Dosw (Online); 2012 Jun; 66():339-47. PubMed ID: 22706120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Importance of minimal residual viremia for relapse prediction in patients with chronic hepatitis C genotype 1 infection.
    Wiegand J; Neumann K; Böhm S; Weich V; Teuber G; Klinker H; Möller B; Rasenack J; Hinrichsen H; Gerlach T; Spengler U; Buggisch P; Sarrazin C; Berg T
    Clin Infect Dis; 2011 Dec; 53(11):1111-4. PubMed ID: 22021919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.